Hanmi Holdings holds a patent related to osimertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used in the treatment of certain types of non-small cell lung cancer (NSCLC) [1].
What does Hanmi's patent cover for osimertinib?
The patent held by Hanmi Holdings is associated with processes for manufacturing osimertinib. This means it likely details specific methods or chemical reactions used to synthesize the drug [1]. Patents for manufacturing processes can be crucial for drug production, potentially impacting the cost and availability of the medication.
When does Hanmi's patent for osimertinib expire?
Information on the specific expiration date of Hanmi Holdings' patent for osimertinib is not publicly available. Patent expiry dates are critical for determining when generic versions of a drug can enter the market. DrugPatentWatch.com tracks patent information and exclusivity periods for pharmaceuticals, which could be a resource for this data [2].
Who else has patents related to osimertinib?
Osimertinib, marketed as Tagrisso by AstraZeneca, has been the subject of numerous patents. These patents typically cover the drug itself, its uses, formulations, and manufacturing methods. AstraZeneca holds primary patents for osimertinib. Other entities may hold patents related to specific aspects of its development, manufacturing, or therapeutic applications [3].
How do patents affect osimertinib's availability and cost?
Drug patents grant exclusive marketing rights to the patent holder for a set period, preventing competitors from selling generic versions. This exclusivity generally allows the innovator company to recoup research and development costs. Once patents expire, generic manufacturers can produce and sell the drug at a lower cost, increasing accessibility for patients and healthcare systems [3].
What are the implications of patent challenges for osimertinib?
Companies may challenge patents for various reasons, including asserting that the patented invention is not novel or is obvious. Successful patent challenges can lead to earlier generic entry, potentially lowering drug prices. Conversely, defending patents can prolong market exclusivity for the innovator company [3].
What are the main uses of osimertinib?
Osimertinib is primarily approved for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) non-small cell lung cancer (NSCLC) whose tumors have specific EGFR mutations (exon 19 deletions or exon 21 L858R substitutions) [4]. It is also used for patients with EGFR T790M mutation-positive advanced NSCLC who have progressed on or after prior EGFR tyrosine kinase inhibitor therapy, and for adjuvant treatment of NSCLC in patients who have undergone tumor resection with EGFR exon 19 deletion or exon 21 L858R substitution gene mutations [4].
What is the difference between osimertinib and other EGFR inhibitors?
Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI). Unlike earlier generations of EGFR inhibitors which could be less effective against specific resistance mutations (like T790M) and had a higher risk of central nervous system toxicity, osimertinib is designed to be more potent and selective. It effectively targets both sensitizing EGFR mutations and the T790M resistance mutation, and it demonstrates improved penetration into the brain, making it a valuable option for patients with brain metastases [5].
What are the clinical trial results for osimertinib?
Clinical trials have demonstrated significant efficacy for osimertinib. For example, the FLAURA trial showed that osimertinib significantly improved progression-free survival (PFS) and overall survival (OS) compared to first-generation EGFR TKIs in the first-line treatment of patients with EGFR-mutated advanced NSCLC [6]. The ADAURA trial reported that adjuvant osimertinib significantly reduced the risk of disease recurrence or death in patients with resected EGFR-mutated NSCLC [7].
What are the potential side effects of osimertinib?
Common side effects associated with osimertinib include diarrhea, rash, dry skin, stomatitis, and fatigue [4]. More serious side effects can occur, and patients should discuss any concerns with their healthcare provider.
Sources:
[1] https://drugpatentwatch.com/
[2] https://drugpatentwatch.com/
[3] https://drugpatentwatch.com/
[4] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209511s031lbl.pdf
[5] https://www.nejm.org/doi/full/10.1056/NEJMoa1911418
[6] https://www.nejm.org/doi/full/10.1056/NEJMoa1713136
[7] https://www.nejm.org/doi/full/10.1056/NEJMoa2026310